Is AOD 9604 FDA Approved? The Full Regulatory History
No, but AOD 9604 has a more extensive clinical trial history than most compounded peptides. It completed Phase 2 clinical trials in Australia for obesity, enrolling over 300 patients. Australia's Therapeutic Goods Administration (TGA) classified it as safe. The development program was discontinued for efficacy reasons at the Phase 2 dose, not safety concerns.
In this article
AOD 9604 FDA Status at a Glance
FDA Approved?
No. Compounded medication.
Clinical Trials?
Phase 2 completed in Australia (300+ patients)
Safety Classification
TGA (Australia) classified with favorable safety profile
Why Not Approved?
Insufficient efficacy at tested dose, not safety issues
Origin
Monash University, Melbourne, Australia
What It Is
Modified fragment of human growth hormone (amino acids 177-191)
The Short Answer
AOD 9604 is not FDA-approved. However, it has more human clinical trial data than most peptides in compounded use. Phase 2 trials in Australia enrolled over 300 obese patients and demonstrated a clean safety profile. The development program was paused because the efficacy results at the tested doses were modest, not because of any safety signal.
This distinction matters. Many compounded peptides have never been in human trials at all. AOD 9604 went through formal Phase 1 and Phase 2 clinical testing, the TGA reviewed the safety data, and the safety profile was favorable. The gap was in the efficacy data at the oral dose tested, not in the safety evidence.
What Is AOD 9604?
AOD 9604 stands for Advanced Obesity Drug 9604. It was developed by Professor Frank Ng at Monash University in Melbourne as a targeted approach to fat metabolism. The concept was elegant: human growth hormone has powerful fat-burning effects, but it also raises blood sugar, increases IGF-1, and promotes tissue growth. Could you isolate just the fat-burning part?
The answer was amino acids 177 to 191 of the hGH molecule, with a tyrosine residue added at the N-terminus to stabilize the fragment. This 16-amino-acid peptide retained the lipolytic (fat-burning) activity of growth hormone while showing no effect on IGF-1 levels, blood glucose, or growth. It stimulates fat breakdown and inhibits lipogenesis (new fat formation) without the metabolic side effects of full-length growth hormone.
Lipolysis Activation
Stimulates fat cell breakdown through the same beta-3 adrenergic pathway as full-length growth hormone
Lipogenesis Inhibition
Blocks new fat formation, preventing fat cells from refilling after breakdown
No IGF-1 Impact
Does not raise IGF-1 levels, blood sugar, or promote tissue growth unlike full HGH
Fat-Selective
Targets adipose tissue specifically without affecting muscle, bone, or organ growth
Clinical Trials: The Australian Story
1990s
Monash University Development
Professor Frank Ng's lab at Monash University identifies the fat-metabolizing fragment of growth hormone and synthesizes AOD 9604. Preclinical studies confirm fat loss without growth-promoting effects.
2001-2003
Phase 1 Trials
Safety and pharmacokinetic studies in healthy volunteers and obese patients. AOD 9604 is well tolerated with no serious adverse events. Confirms no effect on IGF-1 or blood glucose.
2007
Development Paused
Metabolic Pharmaceuticals reports that the primary efficacy endpoint was not met at a statistically significant level for the oral formulation. Development is paused. The company notes that injectable routes may be more effective but does not pursue further trials.
2000
Metabolic Pharmaceuticals
Metabolic Pharmaceuticals Ltd (ASX-listed biotech) licenses AOD 9604 from Monash University and begins clinical development for obesity treatment.
2004-2006
Phase 2 Trials
Multicenter trials enroll 300+ obese patients testing oral formulation of AOD 9604 at multiple doses. Safety profile remains clean. Efficacy results show modest fat reduction at the doses tested.
2011
TGA Classification
Australia's TGA reviews the safety data and classifies AOD 9604 favorably. The safety evidence from over 300 patients supports a clean profile.
Why AOD 9604 Was Not Approved
The Phase 2 oral formulation did not meet its primary efficacy endpoint for clinically significant weight loss. The fat reduction was real but modest at the oral doses tested. The company noted that the injectable route showed stronger results in earlier testing but did not have the funding to run a new Phase 2 trial with an injectable formulation.
This is a critical nuance: the oral bioavailability of a 16-amino-acid peptide is limited. Much of the orally administered AOD 9604 was likely degraded in the GI tract before absorption. The injectable form, which is what compounding pharmacies now prepare, delivers the peptide directly into systemic circulation at full potency.
Key Takeaway
AOD 9604's clinical trial challenge was efficacy of the oral formulation, not safety. The safety data from 300+ patients was clean. The injectable version used in compounded peptide therapy bypasses the oral bioavailability issue that limited the clinical trial results.
AOD 9604 Today
AOD 9604 is available as a compounded injectable medication in the United States. It is prescribed by licensed providers for body composition optimization, specifically targeting fat reduction without the metabolic side effects of growth hormone therapy. PeRx also offers AOD 9604 in combination with MOTS-C, which addresses fat metabolism through a complementary mitochondrial pathway.
Frequently Asked Questions
Ready to get started?
Pharmaceutical-grade AOD 9604 or the AOD 9604/MOTS-C combination for comprehensive metabolic support. Prescribed by a licensed provider, shipped to your door.
View AOD 9604Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.